Download MendeleyQuinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow, M.D., Ballantine, S.P., Barker, M.D., Clarke, B.J., Dawson, J., Dean, T.W., Delves, C.J., Evans, B., Gough, S.L., Guntrip, S.B., Holman, S., Holmes, D.S., Kranz, M., Lindvaal, M.K., Lucas, F.S., Neu, M., Ranshaw, L.E., Solanke, Y.E., Somers, D.O., Ward, P., Wiseman, J.O.(2009) Bioorg Med Chem Lett 19: 5261-5265
- PubMed: 19656678
- DOI: https://doi.org/10.1016/j.bmcl.2009.04.012
- Primary Citation of Related Structures:
3GWT - PubMed Abstract:
Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable profile for inhaled dosing.
Organizational Affiliation:
Immuno-Inflammation CEDD Medicinal Chemistry Dept, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK. michael.d.woodrow@gsk.com
